Because of the limited experience with T cell redirection treatment strategies in the real world and especially bispecific T cell engagers and CAR T therapies among oncologists and health care professionals outside CAR T administering centers, there is a gap in the understanding, management and utilization of these therapies in patients that might benefit from these types of treatments. As more drug products become available through commercial and research routes, there will be a greater need  for a close partnership between the centers where these treatments are administered and the smaller community centers where the vast majority of oncology patients are typically followed and receive the bulk of their treatments. There is an urgent need to bridge this knowledge gap and raise awareness of novel immune based strategies including antibody drug conjugates, bispecific T cell engagers and CAR T therapies among health care professionals.